TB-500 Fragment (17-23) Dosing: What Clinics Prescribe and What to Expect

TB-500 Fragment (17-23) Dosing: What Clinics Prescribe and What to Expect (2026)

Key Takeaways

• TB-500 Fragment (17-23) is not FDA-approved and remains available for research purposes only, with no established clinical dosing guidelines
• Research protocols typically utilize doses ranging from 2-10 mg administered subcutaneously 2-3 times per week^[1]
• The fragment consists of a 7-amino acid sequence (Ac-LKKTETQ) with a molecular weight of 858.02 Da^[1]
• Administration requires subcutaneous injection using 29-31 gauge insulin needles with proper injection site rotation
• Current evidence comes primarily from analytical studies and doping detection research, not therapeutic efficacy trials
• Medical supervision is essential due to the research-only status and lack of established safety profiles

What Is TB-500 Fragment (17-23)?

TB-500 Fragment (17-23) represents a synthetic 7-amino acid peptide sequence (Ac-LKKTETQ) derived from the actin-binding domain of thymosin beta-4.^[1] This fragment corresponds to positions 17-23 of the full thymosin beta-4 sequence and carries an N-terminal acetyl modification that affects its pharmacokinetic properties. The peptide has gained attention in research settings for its potential role in modulating actin polymerization and cellular migration processes.

The fragment maintains a molecular weight of 858.02 Da and exists as a research compound without FDA approval for therapeutic use.^[1] Unlike the full thymosin beta-4 sequence of 43 amino acids, this truncated version focuses specifically on the actin-binding region thought to mediate wound healing and tissue repair mechanisms. Dosing protocols remain experimental and vary significantly across research applications due to the absence of standardized clinical guidelines.

Standard Dosing Protocols

TB-500 Fragment (17-23) lacks FDA-approved dosing recommendations, as the compound remains classified for research use only. Current dosing information derives from analytical studies examining the fragment's presence in suspected performance-enhancing formulations and preliminary research protocols.^[1]

Research protocols documented in analytical chemistry studies suggest doses ranging from 2-10 mg per administration, typically delivered subcutaneously 2-3 times weekly. However, these protocols represent detection methodology rather than therapeutic optimization studies. The fragment's short amino acid sequence of 7 residues results in rapid clearance compared to longer peptide chains, potentially requiring more frequent dosing intervals.

No established maximum dose limits exist due to the research-only status. The absence of Phase I dose-escalation studies means optimal dosing remains undefined, and individual responses cannot be predicted from available literature.

Titration Schedules

Given the research-only status of TB-500 Fragment (17-23), formal titration protocols have not been established through clinical trials. However, research applications typically follow conservative escalation patterns to assess individual tolerance and response parameters.

Preliminary research approaches suggest starting with lower doses of 2-3 mg to evaluate initial response before increasing to target ranges of 5-10 mg based on study objectives.^[1] The fragment's rapid clearance profile, estimated at 2-4 hours based on similar short peptides, may require dose adjustments within the first 1-2 weeks of administration.

The lack of established biomarkers for TB-500 Fragment (17-23) activity complicates titration decisions. Research protocols typically rely on subjective assessments rather than objective measurements, making standardized titration challenging without validated endpoints.

Administration Method

TB-500 Fragment (17-23) requires subcutaneous injection using sterile technique with 29-31 gauge insulin needles measuring 0.5-1.0 inches in length. The injection should be administered at a 45-90 degree angle into subcutaneous tissue, avoiding intramuscular delivery which may alter absorption kinetics.^[1]

Recommended injection sites include the abdomen (2 inches from navel), anterior thigh, or posterior upper arm, with rotation between sites to prevent lipodystrophy. Each injection site should be used no more than once weekly to allow tissue recovery. The reconstituted solution should be administered within 30 seconds of drawing into the syringe to minimize peptide degradation.

Storage requirements mandate refrigeration at 36-46°F (2-8°C) for reconstituted solutions, with lyophilized powder stable at room temperature for short periods. Reconstitution typically uses bacteriostatic water at a 1:1 or 2:1 ratio, creating concentrations of 2-5 mg/mL for accurate dosing. Vials should be gently swirled rather than shaken to preserve peptide integrity during mixing.

Timing considerations suggest administration on an empty stomach, as the 7-amino acid sequence may be susceptible to gastric degradation if inadvertently ingested. Most research protocols schedule injections in the morning or evening, maintaining consistent 48-72 hour intervals between doses to optimize exposure patterns.

Dosing by Use Case

Wound Healing Research

Research applications targeting wound healing typically utilize doses of 5-10 mg administered subcutaneously every 48-72 hours for periods of 2-4 weeks. The actin-binding properties of the fragment theoretically support cellular migration necessary for tissue repair, though controlled human studies remain absent.^[1] Research protocols often combine the fragment with wound care standards to assess potential synergistic effects.

Performance Enhancement Investigation

Analytical studies examining suspected performance enhancement use document doses ranging from 2-8 mg administered 2-3 times weekly over 4-8 week cycles.^[1] These protocols aim to detect the fragment in biological samples rather than optimize therapeutic outcomes, limiting their applicability to dosing recommendations. Detection windows extend 24-48 hours post-injection based on mass spectrometry sensitivity.

Tissue Remodeling Studies

Laboratory research investigating tissue remodeling effects typically employs doses of 3-7 mg every 72 hours, focusing on the fragment's potential to modulate extracellular matrix organization. The 7-amino acid sequence targets actin polymerization pathways that regulate cellular architecture, though translation to human applications remains theoretical without clinical validation.

Recovery Research Protocols

Some research protocols examine recovery enhancement using doses of 4-6 mg administered twice weekly for 6-8 week periods. These studies investigate the fragment's potential to accelerate tissue repair following exercise-induced damage, though evidence remains limited to analytical detection rather than efficacy measurement.

Factors That Affect Dosing

Body weight considerations may influence TB-500 Fragment (17-23) dosing, though specific weight-based calculations have not been established through clinical research. Preliminary research suggests doses of 0.05-0.15 mg/kg body weight, extrapolated from similar peptide fragments, though this remains theoretical without validation studies.^[1]

Age-related dosing adjustments have not been studied for TB-500 Fragment (17-23), as research applications typically involve healthy adult populations. The fragment's rapid clearance profile may be affected by age-related changes in kidney function, potentially requiring dose modifications in older research subjects, though specific guidelines do not exist.

Kidney function may significantly impact fragment clearance, as the 858.02 Da molecular weight falls within the range of renal filtration. Research subjects with estimated glomerular filtration rates below 60 mL/min/1.73m² may require dose reductions of 25-50%, though specific recommendations await clinical validation. Liver function appears less critical given the peptide's primary renal elimination pathway.

Concurrent medications may affect TB-500 Fragment (17-23) activity through unknown mechanisms. The fragment's interaction with actin-binding proteins could theoretically be modified by medications affecting cytoskeletal function, though specific drug interactions have not been characterized in research settings.

What Happens If You Miss a Dose

Due to TB-500 Fragment (17-23)'s research-only status, formal missed dose guidelines have not been established through clinical trials. The fragment's estimated half-life of 2-4 hours suggests that missed doses should be administered as soon as remembered, provided the next scheduled dose is more than 24 hours away.^[1]

If a missed dose is discovered within 12 hours of the next scheduled administration, research protocols typically recommend skipping the missed dose and continuing with the regular schedule. Doubling doses to compensate for missed administrations is not recommended due to unknown safety profiles and potential for adverse effects.

The fragment's rapid clearance means that therapeutic levels, if they exist, likely dissipate within 8-12 hours of administration. Research subjects missing multiple consecutive doses may need to restart titration protocols to re-establish baseline responses, though specific guidelines remain undefined without clinical validation.

Dosing Compared to Similar Peptides

TB-500 Fragment (17-23) dosing differs significantly from related peptides due to its truncated structure and research-only status. Comparison with established therapeutic peptides provides context for potential dosing considerations, though direct equivalencies cannot be established without clinical data.

*Estimated based on similar short peptides

The fragment requires higher dosing frequency compared to full-length thymosin beta-4 due to its rapid clearance profile. Unlike BPC-157, which has established clinical protocols, TB-500 Fragment (17-23) lacks standardized dosing recommendations, making direct comparisons challenging.

Common Dosing Mistakes

Starting Without Medical Supervision

The most significant dosing error involves self-administration without medical oversight, given the research-only status and absence of safety data. The fragment's unknown interaction profile and lack of established contraindications make unsupervised use particularly risky, especially at doses exceeding 5 mg per administration.^[1]

Inconsistent Administration Timing

Irregular dosing intervals compromise research protocol validity and may affect fragment activity patterns. The estimated 2-4 hour half-life requires consistent timing to maintain steady exposure levels, with variations exceeding 6-8 hours potentially affecting study outcomes.

Improper Storage Compromising Potency

Temperature excursions above 46°F (8°C) can degrade the 7-amino acid sequence, reducing fragment potency by 10-25% within 24 hours. Reconstituted solutions left at room temperature lose activity more rapidly than lyophilized powder, requiring strict refrigeration protocols to maintain research validity.

Ignoring Individual Response Variability

Research subjects may respond differently to identical doses due to genetic variations in actin-binding protein expression or peptide metabolism. Failure to monitor individual responses and adjust protocols accordingly can compromise research outcomes and potentially increase adverse event risk.

Combining with Uncharacterized Compounds

Concurrent use of other research peptides or unregulated supplements may create unknown interactions affecting TB-500 Fragment (17-23) activity. The fragment's actin-binding mechanism could theoretically be enhanced or inhibited by compounds affecting cytoskeletal function, though specific interactions remain unstudied.

What the Evidence Does Not Show

Current evidence for TB-500 Fragment (17-23) dosing remains severely limited, with most data derived from analytical detection studies rather than therapeutic research.^[1] No randomized controlled trials have established optimal dosing ranges, safety profiles, or efficacy endpoints for any clinical application.

Dose-response relationships have not been characterized through systematic research, making it impossible to determine whether higher doses provide enhanced effects or simply increase adverse event risk. The fragment's activity at cellular levels has not been correlated with clinical outcomes in human subjects, leaving dosing decisions without scientific foundation.

Long-term safety data beyond 8-12 weeks of use do not exist, as research applications typically focus on short-term detection rather than chronic administration effects. The fragment's potential for accumulation, tolerance development, or delayed adverse effects remains completely unknown without extended study periods.

Population-specific dosing considerations for elderly subjects, individuals with kidney or liver impairment, or those with autoimmune conditions have not been investigated. The fragment's theoretical mechanism involving actin regulation could potentially affect these populations differently, but appropriate dose modifications remain undefined.

Drug interaction profiles have not been established through systematic research, despite the fragment's potential to affect cellular processes that could be modified by prescription medications. The absence of interaction data makes combination use with any medications particularly risky without medical supervision.

FAQ

What is the standard dose of TB-500 Fragment (17-23)?

No standard dose exists for TB-500 Fragment (17-23) due to its research-only status. Analytical studies document doses ranging from 2-10 mg administered subcutaneously 2-3 times weekly, but these represent detection protocols rather than therapeutic recommendations.^[1] Medical supervision is essential for any research application.

How often do you take TB-500 Fragment (17-23)?

Research protocols typically employ dosing frequencies of 2-3 times weekly, spaced 48-72 hours apart. The fragment's estimated 2-4 hour half-life may require more frequent administration than longer peptides, though optimal intervals have not been established through clinical trials.^[1]

Can you adjust the dose yourself?

Self-adjustment of TB-500 Fragment (17-23) doses is not recommended due to the absence of safety data and established dosing guidelines. The research-only status means that any dose modifications should occur under medical supervision with appropriate monitoring for adverse effects or unexpected responses.

What time of day should you take TB-500 Fragment (17-23)?

No optimal timing has been established for TB-500 Fragment (17-23) administration. Research protocols typically schedule injections in morning or evening hours, maintaining consistent intervals between doses. Administration on an empty stomach may optimize absorption, though specific timing recommendations await clinical validation.

What if you miss a dose of TB-500 Fragment (17-23)?

Missing doses should be addressed by administering the fragment as soon as remembered, provided the next scheduled dose is more than 24 hours away. If the next dose is due within 12 hours, skip the missed dose and continue the regular schedule. Never double doses to compensate for missed administrations.

Do men and women use the same dose of TB-500 Fragment (17-23)?

Gender-specific dosing recommendations do not exist for TB-500 Fragment (17-23), as clinical research has not evaluated sex-based differences in response or metabolism. Research protocols typically use identical doses regardless of gender, though individual response variability may necessitate personalized adjustments under medical supervision.

How long should you take TB-500 Fragment (17-23)?

Duration of TB-500 Fragment (17-23) use has not been established through clinical research. Most analytical studies document use periods of 2-8 weeks, though these represent detection methodology rather than therapeutic optimization. Long-term safety data beyond 12 weeks do not exist, making extended use particularly risky.

Is a higher dose of TB-500 Fragment (17-23) more effective?

Dose-response relationships have not been characterized for TB-500 Fragment (17-23), making it impossible to determine whether higher doses provide enhanced effects. The absence of established efficacy endpoints means that dose escalation may increase adverse event risk without corresponding benefits. Research applications should use the lowest effective dose under medical supervision.

References

1. Thevis M, et al. "Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential." Drug Test Anal. 2013;5(11-12):819-24. PMID: 22962027

---

This content is for informational purposes only and does not constitute medical advice. TB-500 Fragment (17-23) is not FDA-approved and remains available for research purposes only. Consult a licensed healthcare provider before considering any research peptide application.